Senzime: Preliminary results to be presented at IARS 2017



Uppsala, March 13, 2017. Senzime AB (publ) is happy to announce that the abstract authored by Dr. J. Ross Renew from the Mayo Clinic and entitled, “Examining Awake Volunteer Pain Scores and Operator Ease of Use of a Novel Neuromuscular Blockade Monitor” was accepted for publication. The volunteer study compared the TetraGraph and TOF-Watch, and the results will be presented at IARS (International Anesthesia Research Society) 2017 Annual Meeting and International Science Symposium, in Washington DC, May 6-9.


The scientific abstract will be published in the journal Anesthesia & Analgesia, the official journal of the International Anesthesia Research Society that all members receive as a benefit of membership.

About the study: Senzime, in collaboration with the principal investigator Dr. J. Ross Renew, a recognized researcher in the area of neuromuscular pharmacology and physiology at Mayo Clinic’s Jacksonville, Florida USA location, carried out a validation study in awake volunteers to evaluate TetraGraph’s ease of use, required set-up time, and the discomfort associated with neurostimulation. The TetraGraph was compared with the existing neuromuscular monitor that is based on acceleromyography, the TOF-Watch.

Every year over 70 million surgical patients undergo general anesthesia and receive neuromuscular blocking drugs. Without objective monitoring, over 30 percent of these patients experience postoperative complications.  The TetraGraph monitor is a portable and user-friendly EMG (Electromyography)-based device that allows quantitative neuromuscular monitoring in settings where motion detection (acceleromyography) is not possible.

Prof. Sorin Brull from the Mayo Clinic will be presenting the results of this study, and Senzime will exhibit at the meeting - please come and visit us at the stand!

For further information, please contact:

Lena Söderström, CEO Senzime

Tel: +46 (0)708 16 39 12, e-post: lena.soderstrom@senzime.com

TO THE EDITORS 

About Senzime

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of $10 billion. The company's shares are listed on AktieTorget (ATORG: SEZI) www.senzime.com 




Publicerat: 3/13/2017 8:55:01 AM


  • Mäster Samuelsgatan 42
  • 111 57 Stockholm
  • Telefon: 08 - 511 68 000
  • info(snabel-a)aktietorget(punkt)se